Download our whitepaper,
Rare Dermatological Diseases:
Specialized Trial Approaches
What's Inside:
- Trial design strategies for ultra-rare skin conditions.
- Natural history studies and disease registries.
- Wound healing assessments in epidermolysis bullosa.
- Patient burden and trial feasibility considerations.
- Orphan drug designation for rare dermatoses.
- Gene therapy and regenerative approaches.
Access your complimentary whitepaper today:
Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is a multifaceted autoimmune condition predominantly characterized by skin manifestations, which can occur independently or as part of systemic lupus erythematosus (SLE).
Encompassing acute, subacute, and chronic subtypes, CLE presents a spectrum of clinical features, including photosensitivity, distinctive rashes, and potential for scarring. While primarily affecting the skin, the disease may progress to systemic involvement in a subset of patients, necessitating comprehensive diagnostic and therapeutic strategies.
Our whitepaper provides an in-depth exploration of CLE, examining its pathophysiology, diagnostic criteria, epidemiology, and the latest advancements in therapeutic approaches.
At iNGENū, we are dedicated to advancing the understanding and treatment of Cutaneous Lupus Erythematosus. Through cutting-edge research and a patient-centered approach, our mission is to deliver innovative solutions that improve the lives of individuals and families impacted by this challenging condition.
3–6x
Women are affected more often than men
4
cases per 100,000 people annually
20–50
Most common between the ages of 20–50
Our clinical team has over
120
years of combined clinical trial experience